- $1.67bn
- $1.43bn
- $62.90m
Brief: Nuvation Bio To Report Third Quarter 2026 Financial Results And Provide Business Update On November 4, 2026
U.S. RESEARCH ROUNDUP-Everpure, Marvell Technology, Okta
Nuvation Bio Inc. reports results for the quarter ended June 30 - Earnings Summary
Nuvation Bio Q2 revenue beats estimates on IBTROZI growth
Brief: Nuvation Bio To Report Second Quarter 2026 Financial Results
U.S. STOCKS ON THE MOVE-Yum Brands, AMD, Nuvation Bio
U.S. STOCKS ON THE MOVE-Yum Brands, AMD, Nuvation Bio
Nuvation Bio rises as brain cancer drug data spur expansion of studies
U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
U.S. STOCKS ON THE MOVE-Fortrea, Nuvation Bio, Acadia Pharmaceuticals
Nuvation Bio falls on upsized $250 mln convertible bond offering
Nuvation Bio slides on planned $200 mln convertible offering
Brief: Nuvation Bio Announces Proposed Convertible Senior Notes Offering
Brief: Nuvation Bio To Collaborate With Thermo Fisher Scientific For U.S.-Based Manufacturing Of Ibtrozi For Ros1-Positive Non-Small Cell Lung Cancer
Nuvation Bio Q1 net income turns positive on IBTROZI sales
Brief: Nuvation Bio Q1 EPS USD 0.01
Brief: Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (Ibtrozi®) As Recommended Option
U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences